News Column

DERMA SCIENCES, INC. FILES (8-K) Disclosing Regulation FD Disclosure, Financial Statements and Exhibits

January 21, 2014

Item 7.01. Regulation FD Disclosure On January 16, 2014 , Derma Sciences, Inc. (the "Company") issued a press release announcing record revenues for the fourth quarter and fiscal year ended December 31, 2013 , introducing revenue guidance for 2014 and providing an update on DSC127 Phase 3 clinical trials. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed "filed" for any purpose. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated January 16, 2014 of Derma Sciences, Inc. Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DERMA SCIENCES, INC. By: /s/ John E. Yetter John E. Yetter , CPA Executive Vice President, Finance and Chief Financial Officer Date: January 21, 2014 Exhibit Number Description 99.1 Press Release dated January 16, 2014 of Derma Sciences, Inc.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools